<DOC>
	<DOCNO>NCT01494090</DOCNO>
	<brief_summary>Statins ( HMG-CoA reductase inhibitor ) largely proven efficacy primary secondary prevention cardiovascular event . Many clinical experimental study support also potential beneficial effect statin therapy venous thromboembolism ( VTE ) . Patients hip fracture high risk VTE cardiovascular event . The aim study evaluate efficacy tolerance statin ( rosuvastatin ) hip fracture surgery occurrence venous atherothrombotic event global mortality six month . Subjects age 60 year schedule undergo surgery fracture upper portion femur ( hip fracture ) eligible participate multicentre , randomize , double-blind placebo control trial . They receive either rosuvastatin ( 5 20 mg ) placebo 6 month . The primary efficacy outcome incidence adjudicate composite non fatal VTE , acute coronary syndrome , non fatal stroke , acute ischemic arterial event , all-cause death . Assuming endpoint frequency 20 % control group , calculated 1200 patient require study 80 % power detect 30 % reduction relative risk rosuvastatin ( two-sided alpha level 5 % ) . The investigator assume rosuvastatin could positive benefit-risk ratio patient undergo orthopaedic surgery hip fracture , reduce vascular event global mortality six month .</brief_summary>
	<brief_title>Statin Hip Fracture</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>60 year old old . fracture femoral neck trochanteric mass undergoing surgery within 5 day fracture Signed write informed consent contraindication rosuvastatin : active liver disease include unexplained prolonged elevation serum transaminase increase serum transaminase beyond 3 time upper limit normal severe renal impairment ( creatinine clearance calculate formula MDRD &lt; 30 ml / min ) myopathy use cyclosporine statin therapy ongoing admission fracture curative anticoagulant therapy ongoing admission expect maintain intervention Patients consider investigator unable participate study Refuse participate</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Hip fracture</keyword>
	<keyword>Cardiovascular event</keyword>
	<keyword>Statin</keyword>
</DOC>